KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Debt (2016 - 2025)

Jazz Pharmaceuticals has reported Total Debt over the past 16 years, most recently at $5.4 billion for Q4 2025.

  • Quarterly results put Total Debt at $5.4 billion for Q4 2025, down 12.28% from a year ago — trailing twelve months through Dec 2025 was $5.4 billion (down 12.28% YoY), and the annual figure for FY2025 was $5.4 billion, down 12.28%.
  • Total Debt for Q4 2025 was $5.4 billion at Jazz Pharmaceuticals, roughly flat from $5.4 billion in the prior quarter.
  • Over the last five years, Total Debt for JAZZ hit a ceiling of $6.7 billion in Q2 2021 and a floor of $2.1 billion in Q1 2021.
  • Median Total Debt over the past 5 years was $5.7 billion (2023), compared with a mean of $5.6 billion.
  • Biggest five-year swings in Total Debt: surged 220.39% in 2021 and later decreased 12.28% in 2025.
  • Jazz Pharmaceuticals' Total Debt stood at $6.0 billion in 2021, then dropped by 5.38% to $5.7 billion in 2022, then fell by 0.2% to $5.7 billion in 2023, then rose by 6.93% to $6.1 billion in 2024, then dropped by 12.28% to $5.4 billion in 2025.
  • The last three reported values for Total Debt were $5.4 billion (Q4 2025), $5.4 billion (Q3 2025), and $5.4 billion (Q2 2025) per Business Quant data.